Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06012253
Other study ID # "70904504/376"
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 15, 2023
Est. completion date September 30, 2024

Study information

Verified date June 2024
Source Akdeniz University Hospital
Contact Hava Kara
Phone +905547267943
Email bilgin008@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study aims to evaluate the effect of home-based walking program on peripheral neuropathy, fatigue and quality of life in patients receiving taxane and platinum-based chemotherapy.


Description:

The study was designed as a randomized controlled trial. This study will be carried out with a total of 86 cancer patients receiving taxane and platinum-based chemotherapy, 43 of whom were in the intervention group and 43 in the control group, whose treatment was started in Akdeniz University Hospital."Home Based Walking Program" will be applied to the patients in the intervention group for 8 weeks.Within the scope of the Home-Based Walking Program, face-to-face patient education, patient education booklet, sending text messages, face-to-face and telephone counseling were planned. Patient Identification Form, International Physical Activity Questionnaire (IPAQ- Short Form), National Cancer Institute (NCI) -CTCAE v5.0 Toxicity Criteria, Cancer Fatigue Scale, EORTC QLQ-CIPN20 (Quality of Life Chemotherapy-Induced Peripheral Neuropathy) and EORTC QLQ-C30 (Quality of Life Scale), Interview Form will be used to collect data.


Recruitment information / eligibility

Status Recruiting
Enrollment 86
Est. completion date September 30, 2024
Est. primary completion date August 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria - 18 Years and older (Adult, Older Adult ) - Turkish speaking-understanding ability and literate. - Orientation (person, place, time) - Receiving taxane and platinum-based chemotherapy treatment (monotherapy or combined). - Receiving chemotherapy treatment for the first time. - The primary medical diagnosis is cancer (breast cancer, colorectal cancers and other cancers). - Not having health problems that prevent walking. - Agreeing to participate in the research. Exclusion Criteria - Being bone and brain metastases - Being peripheral neuropathy due to reasons other than chemotherapy (such as chronic disease, diabetes mellitus, nutritional disorders) - Skin sensitivity on the hands and feet - Having cardiovascular, pulmonary, musculoskeletal, or psychological disorders that limit exercise or mobility - Being in another supportive program - Being in the very active category according to the "International Physical Activity Scale (IPAQ- Short Form)" - Being a severity of more than 4 points according to the "Modified Borg Scale (MBS)" - Being a score of 2 and above according to the "ECOG Performance Scale"

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Home Based Walking Program
The intervention group will be applied to "Home Based Walking Program". It was aimed that the patients should do at least 150 minutes of moderate-intensity physical exercise per week for up to 8 weeks. The content of the program includes a walking information booklet (information notes, activity chart and obstacle avoidance form), exercise diary, face-to-face-telephone counseling, sending text messages, prepared in line with international guides. It was planned to give weekly counseling to the patients included in the intervention group for an 8-week period.

Locations

Country Name City State
Turkey Akdeniz University Konyaalti Antalya

Sponsors (1)

Lead Sponsor Collaborator
Akdeniz University Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary International Physical Activity Questionnaire (IPAQ- Short Form) It is used to evaluate physical activity. The form includes walking, moderate and vigorous activity, sitting categories. The total score includes the sum of time (minutes) and frequency (days). Baseline and 8th week
Primary National Cancer Institute (NCI) -CTCAE v5.0 Toxicity Criteria This scale was developed to evaluate the grading of chemotherapy-related peripheral neurotoxicity. It evaluates sensory and motor neuropathy between grades 1-5. Baseline and 8th week
Primary Cancer Fatigue Scale This scale was developed to evaluate the fatigue of cancer patients. It includes 15 questions and three sub-dimensions: Physical, Affective and Cognitive. The Likert type form is evaluated by giving points. Increasing scores received from the scale demonstrate a high level of fatigue. Baseline and 8th week
Primary European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy (EORTC QLQ-CIPN 20) This scale was developed to evaluate the effect of peripheral neuropathy on quality of life of cancer patients. It includes 20 questions and three sub-dimensions: Sensory, Motor and Autonomic. The Likert type form is evaluated by giving points. Increasing scores received from the scale demonstrate a high level of symptoms and problems related to peripheral neuropathy. Baseline and 8th week
Primary European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) This Scale was developed to measure the quality of life of patients with cancer. It includes 30 questions and three sub-dimensions: Global health status, Functional, Symptom. High scores in the functional subscale indicate good/healthy functional status, high scores in the symptom subscale indicate high levels of symptoms and/or problems, and high scores in the global health status/quality of life subscale indicate good quality of life. Baseline and 8th week
See also
  Status Clinical Trial Phase
Completed NCT04277650 - System for High-Intensity Evaluation During Radiotherapy N/A
Recruiting NCT05959720 - Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
Recruiting NCT06041477 - Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC Phase 3
Recruiting NCT06421610 - OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion. Phase 1
Recruiting NCT06197581 - Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer N/A
Not yet recruiting NCT04965532 - Residual Neuromuscular Block of Rocuronium in Chemotherapy Patients Under Sevoflurane Anesthesia N/A
Completed NCT04843410 - Effect of Exercise in the Management of Peripheral Neuropathy N/A
Enrolling by invitation NCT04027478 - Can Fasting Decrease the Side Effects of Chemotherapy? N/A
Terminated NCT04607668 - Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): Phase 3
Completed NCT05635929 - Oral Mucositis and Quality of Life With a Mucosa Topical Composition in Head & Neck Cancer Patients. N/A
Recruiting NCT06357871 - Role of Renal Biopsy in the Suspicion of Nephrotoxicity of Immunotherapy (Checkpoint Inhibitors) in Solid Cancer
Completed NCT02996201 - Electronic Patient Reporting of Side Effects to Chemotherapy: A Cluster Randomized Controlled Trial N/A
Completed NCT00292526 - Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients Phase 4
Completed NCT04663178 - Foot Bath and Chemotherapy Induced Fatigue N/A
Recruiting NCT03191461 - Myocardial Perfusion and Fibrosis in Cancer Survivors
Recruiting NCT05251922 - Tolerance of Anti-Cancer Therapy in the Elderly
Not yet recruiting NCT06387901 - Investigating Paclitaxel Toxicity in Breast Cancer: The Roles of Physical Activity and Body Composition.
Recruiting NCT05892146 - Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction N/A
Not yet recruiting NCT05921149 - Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer N/A
Recruiting NCT05302336 - AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer Phase 4